Latest News and Press Releases

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code,  J1454, in the US, by the...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between...

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between...

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code,  J1454, in the US, by the...

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO,...

The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer patients LUGANO, SWITZERLAND, AND NEW YORK, NY,...

Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...

Helsinn Group strengthens the Board with the appointment of Francesco Granata  LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...

Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting Lugano, Switzerland, September 26, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...